Quest Diagnostics to acquire Celera
Dr. Surya N. Mohapatra, chairman and CEO of Quest Diagnostics, says the $344 million deal "advances our growth strategy to be the leading innovator and provider of esoteric and gene-based testing for cancer" as well as cardiovascular disease, infectious disease and neurological disorders.
Cephalon to purchase all Gemin X outstanding capital stock for $225 million
Cephalon calls Gemin X's array of novel, targeted cancer therapeutics "a welcome addition to our current oncology portfolio."
Gilead, Yale collaboration to target novel cancer therapies
"The collaboration," says Richard C. Levin, president of Yale's School of Medicine, "brings together one of the world's top research universities and a biopharmaceutical company dedicated to addressing unmet medical needs with the goal of finding new treatments for cancer."
New melanoma drug from BMS gets approval from FDA
Bristol-Myers Squibb Co.'s Yervoy (ipilimumab) will benefit patients with unresectable (inoperable) or metastatic melanoma, making it the first new drug to be approved for such cancer in around 10 years.
U.K. researchers: Blocking 'rogue' gene could stop the spread of most cancers
Scientists at the University of East Anglia say they have discovered a "rogue" gene which, if blocked by the right drugs, could stop cancer in its tracks.